<DOC>
	<DOCNO>NCT00934752</DOCNO>
	<brief_summary>The study enroll patient angiographically significant coronary de novo lesion . Subjects randomize 1:1 treated Lutonix catheter either bare-metal stenting ( BMS ) . The purpose ass feasibility , safety efficacy Lutonix Catheter treatment de novo coronary artery stenosis use two distinct treatment strategy .</brief_summary>
	<brief_title>De Novo Pilot Study , Lutonix Catheter Conjunction With Bare Metal Stenting Treatment Coronary De Novo Lesions</brief_title>
	<detailed_description />
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male nonpregnant/nonbreast feed Female ≥ 18 year age . Women childbearing potential must negative pregnancy test ( within 7 day procedure ) ; Documented stable angina pectoris Canadian Cardiovascular Society Classification ( CCSC ) 14 , unstable angina pectoris document ischemia ( Braunwald III ) document silent ischemia ; Left ventricular ejection fraction ( LVEF ) ≥ 25 % ; Patient acceptable candidate PTCA , stenting , emergent coronary artery bypass grafting ( CABG ) ; Patient willing provide inform consent comply followup visit test schedule ; Target lesion de novo lesion native coronary artery vessel ; Initial stenosis ≥ 50 % &lt; 100 % visual estimate quantitative coronary angiography ( QCA ) ; Reference Vessel Diameter ( RVD ) ≥ 2.5 ≤ 3.25 prior predilation ; Target lesion ≤18mm length treat entirety 1 single Lutonix Catheter balloon 1 single BMS ; Guidewire able cross lesion place distal vessel prior enrollment ; Enrollment permit successful treatment 1 nonstudy lesion single nonstudy vessel ( vascular territory study lesion ) . Successful treatment define ≤ 30 % residual stenosis Thrombolysis Myocardial Infarction ( TIMI ) Grade III flow evidence dissection . History stroke within past 6 month ; History myocardial infarction ( MI ) thrombolysis within 72 hour randomization ; Prior vascular brachytherapy ; Uncontrollable allergy procedure medication , material contrast ; Angiographic evidence thrombus dissection within target vessel ; Intervention another coronary lesion ≤ 60 day index procedure day plan follow index procedure ; Target lesion plan treated something PTCA stent ( i.e. , cuttingballoon , atherectomy , vascular brachytherapy ( VBT ) , etc . ) ; Target lesion Left Main excessive calcification tortuosity involve bifurcation disease vessel ≥ 2.5mm ; Known sensitivity receive paclitaxel antimitogenic agent within 12 month prior target vessel treatment ; Patient previous intervention ( PTCA , stent , etc . ) target coronary vessel ; Any medical condition , investigator opinion , preclude patient study patient life expectancy le 24 month ; Known creatine kinaseMB ( CKMB ) &gt; 2x upper limit normal ( ULN ) positive Troponin ; Creatinine &gt; 2.0 mg/dl ; Leukocyte &lt; 3500/mL ; Platelet &lt; 100,000 mL &gt; 750,000 mL ; Currently take must resume warfarin ; Patient contraindicate antiplatelet therapy need withdrawn plan procedure ; The subject currently participate another investigational drug device study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>de novo stenotic lesion</keyword>
</DOC>